Hage C, et al. - Given that withdrawal of dopamine agonist (DA) therapy in patients with prolactinoma who are controlled by a small dose of medication is recommended by several guidelines, researchers retrospectively investigated early clinical, radiological, or biochemical characteristics that may predict the likelihood of reaching withdrawal conditions in prolactinoma patients. Of 213 patients, 78 (36.6%) had met criteria of withdrawal after at least two years of DA treatment. For most prolactinoma patients, DA remains a potential life-long treatment modality. Long-term therapy is more likely to be needed in patients with parasellar invasiveness and low prolactin percent shift from baseline to first prolactin check.